Speeding up drug discovery – Glyconet & 48Hour Discovery
48Hour Discovery and Glyconet were recently featured by Global News https://globalnews.ca/video/8705661/health-matters-speeding-up-drug-discovery-new-covid-19-variant-now-dominant-in-alberta/
All-In-One Solutions For Ligands Discovery
48HD uses genetically encoded phage displayed peptide and peptide derived libraries to discover target ligands. With over one billion medium sized peptides (200-3000 Dalton), the library ensures a “sweet spot” in protein-ligand recognition, unlike small molecule and antibody-based therapeutics. Four in-house encoded, proprietary libraries are currently available for screening services.
Search Billions of Peptides
We accelerate discovery to find new and better drugs. Our patented technology, which combines phage display and next generation sequencing, can screen billions of unique peptides within weeks.
Reduce Lead Time
48 Hour Discovery has a powerful new technology platform for peptide-based drug discovery. Our technology can discover drug leads in days rather than months.
Streamline your R&D
Our unique platform enables the rapid identification of both standard and macrocyclic peptides, which exhibit excellent potency, selectivity, and GI stability for oral delivery.
Drug discovery is a complex process that can cost billions of dollars but there are innovations at every step of the process that make this process more streamlined and thereby lower its cost
Ratmir Derda – CEO 48Hour Discovery
48Hour Discovery
Using innovative technology to find entirely unique solutions
With 48Hour Discovery’s technology—part chemistry, part artificial intelligence—potential drug targets are retrieved using the interaction between target proteins from, for instance, a cancer cell and a molecule library in a test tube.
We use phage display and high throughput next-generation sequencing to identify peptide ligands with high affinity for promising drug targets from billion-scale libraries of molecules.
Innovators
We help pharmaceutical companies advance in medicine
Meet our Team
Meet the people behind our pipeline that make the magic happen
For Investors
Take a look at our investors page for some more company information
Single Round ScreeninG
Single-round screening is applied when protein targets have defined binding sites e.g. antibodies. The outcome of such screening are linear epitope mapping or immunoprofiling. We recommend clients use our in-house linear or cyclic libraries
Multi-Round Screening
Multi-round screening is used to probe protein-protein interactions, or when targets are more complex, e.g. with shallow binding sites, or targets that form complex. In this case, we recommend clients using our cyclic, bicyclic, or GE-FBD/customized libraries.
Cloud Database
We operate a proprietary cloud database service to store all results. This service enables access to results from anywhere in the world, with any device. In addition, search data that some academic partners have made public is available.
Leadership
Put a face to our executive leadership members
Ratmir Derda
Founder & CEO
Jessica (Yun) Cao
VP of Data Science and Information Technology
David Alton
VP of Finance & Business Development
Martin Truksa
VP of Research and Development
PRESS RELEASES
48HD is profiled as a top glycomics company in a new Glyconet report.
As with genomics 20 years ago, glycomics is at a critical stage, a tipping point. Glycomics is expected
48Hour Discovery and Fusion Pharmaceuticals to Develop Radiopharmaceuticals for the Treatment of Cancer Tumours
The goal of the collaboration is to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumours.
